Autopsy report · NCT00746941

Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

“Primary endpoint not achieved”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 1 year 10 months before it stopped.
• 37 participants enrolled.
• Results were posted on the registry 3 years 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Biogen

Sponsor type

Industry

Conditions

Progressive Multifocal Leukoencephalopathy

Interventions

mefloquine

Participants

37

Sites

12

Countries

Brazil, Germany, Italy, Spain, United States

Trials that died the same way

• CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
  “Primary Endpoint not met” (93% match in meaning)
• Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
  “primary endpoint was not met” (92% match in meaning)
• Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms
  “Primary Endpoint met” (82% match in meaning)
• Cytokines and the Risk of Infection in Liver Cirrhosis
  “Finding to be unable to reach the primary endpoint” (81% match in meaning)
• A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
  “Primary (safety) endpoint reached” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.